Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PENICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PENICILLIN VK.
LAROTID vs PENICILLIN-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Penicillin VK inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
250-500 mg orally every 6-8 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections (e.g., streptococcal pharyngitis, skin infections).
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5 hours (normal renal function); prolonged to 3-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: 20-40% unchanged via tubular secretion; hepatic metabolism to penicilloic acid; biliary/fecal: minimal (<5%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic